Charles Kennergren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles Kennergren has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Pietro Maggioni
Centro Studi ANMCO—Heart Care Foundation, 50121 Florence, Italy
2 shared publications - Angelo Auricchio
Department of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale , Lugano
2 shared publications - Christian Butter
Department of Cardiology, Immanuel Clinic Bernau, Heart Center Brandenburg, Bernau, Germany
2 shared publications - Christopher Aldo Rinaldi
Guy’s and St Thomas’ Hospital & School of Biomedical Engineering and Imaging Sciences, King’s College London Department of Cardiology Westminster Bridge Road, London SE1 7EH
2 shared publications - Daniel R. Lexcen
Cardiac Rhythm Heart FailureMedtronic, Inc. Minneapolis MN
2 shared publications - Jean-Claude Deharo
Assistance Publique − Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie , Marseille
2 shared publications
Latest Publications
- Open Access
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1073-1082
Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial
Background - In the WRAP-IT trial, adjunctive use of an absorbable antibacterial envelope resulted in a 40% reduction of major cardiac implantable electronic device (CIED) infection without increased risk of complication in 6,983 patients undergoing CIED revision, replacement, upgrade, or initial cardiac resynchronization therapy defibrillator (CRT-D) implant. There is limited information on the cost-effectiveness of this strategy. As a pre-specified objective, we evaluated antibacterial envelope cost-effectiveness compared to standard-of-care infection prevention strategies in the US healthcare system. Methods - A decision tree model was used to compare costs and outcomes of antibacterial envelope (TYRX) use adjunctive to standard-of-care infection prevention vs. standard-of-care alone over a lifelong time horizon. The analysis was performed from an integrated payer-provider network perspective. Infection rates, antibacterial envelope effectiveness, infection treatment costs and patterns, infection-related mortality, and utility estimates were obtained from the WRAP-IT trial. Life expectancy and long-term costs associated with device replacement, follow-up, and healthcare utilization were sourced from the literature. Costs and quality-adjusted life years (QALYs) were discounted at 3%. An upper willingness-to-pay (WTP) threshold of $150,000 per QALY was used to determine cost-effectiveness, in alignment with American College of Cardiology and American Heart Association (ACC/AHA) practice guidelines and as supported by the World Health Organization (WHO) and contemporary literature. Results - The base-case incremental cost-effectiveness ratio (ICER) of the antibacterial envelope compared to standard-of-care was $112,603/QALY. The ICER remained lower than the WTP threshold in 74% of iterations in the probabilistic sensitivity analysis and was most sensitive to the following model inputs: infection-related mortality, life expectancy, and infection cost. Conclusions - The absorbable antibacterial envelope was associated with a cost-effectiveness ratio below contemporary benchmarks in the WRAP-IT patient population, suggesting that the envelope provides value for the US healthcare system by reducing the incidence of CIED infection.
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1073-1082
Open AccessCost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial
Background - In the WRAP-IT trial, adjunctive use of an absorbable antibacterial envelope resulted in a 40% reduction of major cardiac implantable electronic device (CIED) infection without increased risk of complication in 6,983 patients undergoing CIED revision, replacement, upgrade, or initial cardiac resynchronization therapy defibrillator (CRT-D) implant. There is limited information on the cost-effectiveness of this strategy. As a pre-specified objective, we evaluated antibacterial envelope cost-effectiveness compared to standard-of-care infection prevention strategies in the US healthcare system. Methods - A decision tree model was used to compare costs and outcomes of antibacterial envelope (TYRX) use adjunctive to standard-of-care infection prevention vs. standard-of-care alone over a lifelong time horizon. The analysis was performed from an integrated payer-provider network perspective. Infection rates, antibacterial envelope effectiveness, infection treatment costs and patterns, infection-related mortality, and utility estimates were obtained from the WRAP-IT trial. Life expectancy and long-term costs associated with device replacement, follow-up, and healthcare utilization were sourced from the literature. Costs and quality-adjusted life years (QALYs) were discounted at 3%. An upper willingness-to-pay (WTP) threshold of $150,000 per QALY was used to determine cost-effectiveness, in alignment with American College of Cardiology and American Heart Association (ACC/AHA) practice guidelines and as supported by the World Health Organization (WHO) and contemporary literature. Results - The base-case incremental cost-effectiveness ratio (ICER) of the antibacterial envelope compared to standard-of-care was $112,603/QALY. The ICER remained lower than the WTP threshold in 74% of iterations in the probabilistic sensitivity analysis and was most sensitive to the following model inputs: infection-related mortality, life expectancy, and infection cost. Conclusions - The absorbable antibacterial envelope was associated with a cost-effectiveness ratio below contemporary benchmarks in the WRAP-IT patient population, suggesting that the envelope provides value for the US healthcare system by reducing the incidence of CIED infection.
- 18 October 2019
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (12) , 1876-1889
Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry
Aims: The present study sought to determine predictors for success and outcomes of patients who underwent cardiac implantable electronic devices (CIED) extraction indicated for systemic or local CIED related infection in particular where complete lead removal could not be achieved. Methods and results: ESC-EORP ELECTRa (European Lead Extraction ConTRolled Registry) is a European prospective lead extraction registry. Out of the total cohort, 1865/3510 (52.5%) patients underwent removal due to CIED related infection. Predictors and outcomes of failure were analysed. Complete removal was achieved in 1743 (93.5%) patients, partial (4 cm of lead left) in 32 (1.8%) patients. Removal success was unrelated to type of CIED infection (pocket or systemic). Predictors for failure were older leads and older patients [odds ratio (OR) 1.14 (1.08–1.19), P < 0.0001 and OR 2.68 (1.22–5.91), P = 0.0146, respectively]. In analysis by lead, predictors for failure were: pacemaker vs. defibrillator removal and failure to engage the locking stylet all the way to the tip [OR 0.20 (0.04–0.95), P = 0.03 and OR 0.32 (0.13–0.74), P = 0.008, respectively]. Significantly higher complication rates were noted in the failure group (40.6% vs. 15.9 for partial and 8.7% for success groups, P < 0.0001). Failure to remove a lead was a strong predictor for in hospital mortality [hazard ratio of 2.05 (1.01–4.16), P = 0.046]. Conclusion: A total of 6.5% of infected CIED patients failed attempted extraction. Only were >4 cm of lead remained resulted in higher procedural complications and mortality rates.
- 18 October 2019
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (12) , 1876-1889
Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry
Aims: The present study sought to determine predictors for success and outcomes of patients who underwent cardiac implantable electronic devices (CIED) extraction indicated for systemic or local CIED related infection in particular where complete lead removal could not be achieved. Methods and results: ESC-EORP ELECTRa (European Lead Extraction ConTRolled Registry) is a European prospective lead extraction registry. Out of the total cohort, 1865/3510 (52.5%) patients underwent removal due to CIED related infection. Predictors and outcomes of failure were analysed. Complete removal was achieved in 1743 (93.5%) patients, partial (4 cm of lead left) in 32 (1.8%) patients. Removal success was unrelated to type of CIED infection (pocket or systemic). Predictors for failure were older leads and older patients [odds ratio (OR) 1.14 (1.08–1.19), P < 0.0001 and OR 2.68 (1.22–5.91), P = 0.0146, respectively]. In analysis by lead, predictors for failure were: pacemaker vs. defibrillator removal and failure to engage the locking stylet all the way to the tip [OR 0.20 (0.04–0.95), P = 0.03 and OR 0.32 (0.13–0.74), P = 0.008, respectively]. Significantly higher complication rates were noted in the failure group (40.6% vs. 15.9 for partial and 8.7% for success groups, P < 0.0001). Failure to remove a lead was a strong predictor for in hospital mortality [hazard ratio of 2.05 (1.01–4.16), P = 0.046]. Conclusion: A total of 6.5% of infected CIED patients failed attempted extraction. Only were >4 cm of lead remained resulted in higher procedural complications and mortality rates.
- Open Access
- 27 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153651
Coronary Sinus Lead Removal: A Comparison between Active and Passive Fixation Leads
Implantation of coronary sinus (CS) leads may be a difficult procedure due to different vein anatomies and a possible lead dislodgement. The mode of CS lead fixation has changed and developed in recent years. We compared the removal procedures of active and passive fixation leads. Between January 2009 and January 2014, 22 patients at our centre underwent CS lead removal, 6 active and 16 passive fixation leads were attempted using simple traction or lead locking devices with or without laser extraction sheaths. Data on procedural variables and success rates were collected and retrospectively analyzed. The mean patient age was 67.2 ± 9.8 years, and 90.9% were male. The indication for lead removal was infection in all cases. All active fixation leads were Medtronic® Attain StarFix™ Model 4195 (Medtronic Inc., Minneapolis, MN, USA). The mean time from implantation for the active and passive fixation leads was 9.9 ± 11.7 months (range 1.0–30.1) and 48.7 ± 33.6 months (range 5.7–106.4), respectively (p = 0.012). Only 3 of 6 StarFix leads were successfully removed (50%) compared to 16 of 16 (100%) of the passive fixation CS leads (p = 0.013). No death or complications occurred during the 30-day follow-up. According to our experience, removal of the Starfix active fixation CS leads had a higher procedural failure rate compared to passive.
- 27 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153651
Open AccessCoronary Sinus Lead Removal: A Comparison between Active and Passive Fixation Leads
Implantation of coronary sinus (CS) leads may be a difficult procedure due to different vein anatomies and a possible lead dislodgement. The mode of CS lead fixation has changed and developed in recent years. We compared the removal procedures of active and passive fixation leads. Between January 2009 and January 2014, 22 patients at our centre underwent CS lead removal, 6 active and 16 passive fixation leads were attempted using simple traction or lead locking devices with or without laser extraction sheaths. Data on procedural variables and success rates were collected and retrospectively analyzed. The mean patient age was 67.2 ± 9.8 years, and 90.9% were male. The indication for lead removal was infection in all cases. All active fixation leads were Medtronic® Attain StarFix™ Model 4195 (Medtronic Inc., Minneapolis, MN, USA). The mean time from implantation for the active and passive fixation leads was 9.9 ± 11.7 months (range 1.0–30.1) and 48.7 ± 33.6 months (range 5.7–106.4), respectively (p = 0.012). Only 3 of 6 StarFix leads were successfully removed (50%) compared to 16 of 16 (100%) of the passive fixation CS leads (p = 0.013). No death or complications occurred during the 30-day follow-up. According to our experience, removal of the Starfix active fixation CS leads had a higher procedural failure rate compared to passive.
- 14 August 2013
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 24 (3) , 171-175
ELECTRa (European Lead Extraction ConTRolled) Registry—Shedding light on transvenous lead extraction real-world practice in Europe
With the growing recognition of the clinical need and wider indications for cardiovascular implantable electronic devices (CIED), the number of implant procedures has increased considerably. Consequently, the rate of complications related to these devices has also increased. Transvenous lead extraction (TLE) is the gold standard in the treatment of CIED-related infective complications and is often required in the management of lead malfunction. An increasing number of centers currently perform TLE procedures. The ELECTRa (European Lead Extraction ConTRolled) Registry is the first large prospective multicenter registry of consecutive patients undergoing TLE in Europe, conducted by the European Heart Rhythm Association (EHRA) and managed by the European Society of Cardiology (ESC) EURObservational Research Department. The primary objective of the registry is to evaluate the acute and long-term safety of TLE; the secondary objective is to describe the characteristics of the patients, the leads, the indications for TLE, and the tools and techniques currently used for TLE. About 100 centers will be enrolled on a voluntary basis from European countries; they are anonymous and stratified on the basis of their volume of activity into high-volume centers (> 30 patients/year) and low-volume centers: (≤ 30 patients/year). Each participating center will have to enroll and follow up for 1 year consecutively assessed patients undergoing TLE from November 2012 to January 2014. The target is to achieve a sample size of at least 3,500 patients for statistical analysis. Data will be collected using a Web-based system and will be audited at randomly selected centers. The official start was on 6 November. Eighty-nine centers have joined so far, 65 centers are currently active, those who have already obtained the approval of their own ethics committee, and 1,099 patients were enrolled at the end of June 2013. The independence of the registry, the consecutiveness of the patient enrolment, and the monitoring of the study are characteristics of this registry that will contribute to the scientific validity of the objectives to be achieved. Dank der zunehmenden Wahrnehmung eines klinischen Bedürfnisses und breiterer Indikationen, ist die Anzahl an CIED-Implantationen stark angestiegen – und somit auch die Anzahl an Komplikationen, die von diesen Geräten ausgehen. Die Transvenöse Elektrodenextraktion (Transvenous Lead Extraction (TLE)) ist die bewährte Methode für die Behandlung von CIED-bezogenen infektiösen Komplikationen und wird oft im Management von Elektrodenfehlfunktionen gebraucht. Immer mehr Herzzentren bieten nun TLE an. Das ELECTRa (European Lead Extraction ConTRolled)-Register ist das erste großflächige, multizentrische Register für TLE-Patienten in Europa. Es wird von der European Heart Rhythm Association (EHRA) realisiert und von der ESC EURObservational Research Department verwaltet. Primärziel des Registers ist es, die kurz- und langfristige Sicherheit von TLE zu erfassen; sekundär dazu sollen die Patienteneigenschaften, die Elektroden, die Indikationen für TLE, und die Instrumente und Techniken, die aktuell für das Verfahren verwendet werden, beschrieben und festgehalten werden. Rund 100 Herzzentren in europäischen Ländern werden freiwillig teilnehmen; diese werden anonym eingetragen und stratifiziert nach Aktivitätsvolumen in Hochvolumen- (> 30 Patienten/Jahr) und Niedrigvolumenzentren (≤ 30 Patienten/Jahr). Jedes teilnehmende Zentrum muss alle konsekutiv bewertete TLE-Patienten, die zwischen November 2012 und Januar 2014 einer TLE unterzogen wurden bzw. werden, eintragen und 1 Jahr lang nach der OP beobachten. Ziel dabei ist es, einen ausreichend großen Probenumfang für die statistische Analyse zu erreichen (mindestens 3.500 Patienten). Sämtliche Daten werden mit einem webbasierten System gesammelt und in zufällig ausgewählten Zentren überprüft. Offizieller Startschuss war am 6. November 2012. Seitdem haben sich 89 Zentren gemeldet, davon sind 65 – diejenigen, die bereits die Zustimmung des eigenen Ethikkomitees haben – jetzt aktiv. Das Ergebnis: bis Ende Juni 2013 waren bereits 1.099 Patienten eingetragen. Die Unabhängigkeit des Registers, die konsekutive Patienteneintragung und die Überwachung der Studie werden gemeinsam zur wissenschaftlichen Validität der erreichten Zielen beitragen.
- 14 August 2013
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 24 (3) , 171-175
ELECTRa (European Lead Extraction ConTRolled) Registry—Shedding light on transvenous lead extraction real-world practice in Europe
With the growing recognition of the clinical need and wider indications for cardiovascular implantable electronic devices (CIED), the number of implant procedures has increased considerably. Consequently, the rate of complications related to these devices has also increased. Transvenous lead extraction (TLE) is the gold standard in the treatment of CIED-related infective complications and is often required in the management of lead malfunction. An increasing number of centers currently perform TLE procedures. The ELECTRa (European Lead Extraction ConTRolled) Registry is the first large prospective multicenter registry of consecutive patients undergoing TLE in Europe, conducted by the European Heart Rhythm Association (EHRA) and managed by the European Society of Cardiology (ESC) EURObservational Research Department. The primary objective of the registry is to evaluate the acute and long-term safety of TLE; the secondary objective is to describe the characteristics of the patients, the leads, the indications for TLE, and the tools and techniques currently used for TLE. About 100 centers will be enrolled on a voluntary basis from European countries; they are anonymous and stratified on the basis of their volume of activity into high-volume centers (> 30 patients/year) and low-volume centers: (≤ 30 patients/year). Each participating center will have to enroll and follow up for 1 year consecutively assessed patients undergoing TLE from November 2012 to January 2014. The target is to achieve a sample size of at least 3,500 patients for statistical analysis. Data will be collected using a Web-based system and will be audited at randomly selected centers. The official start was on 6 November. Eighty-nine centers have joined so far, 65 centers are currently active, those who have already obtained the approval of their own ethics committee, and 1,099 patients were enrolled at the end of June 2013. The independence of the registry, the consecutiveness of the patient enrolment, and the monitoring of the study are characteristics of this registry that will contribute to the scientific validity of the objectives to be achieved. Dank der zunehmenden Wahrnehmung eines klinischen Bedürfnisses und breiterer Indikationen, ist die Anzahl an CIED-Implantationen stark angestiegen – und somit auch die Anzahl an Komplikationen, die von diesen Geräten ausgehen. Die Transvenöse Elektrodenextraktion (Transvenous Lead Extraction (TLE)) ist die bewährte Methode für die Behandlung von CIED-bezogenen infektiösen Komplikationen und wird oft im Management von Elektrodenfehlfunktionen gebraucht. Immer mehr Herzzentren bieten nun TLE an. Das ELECTRa (European Lead Extraction ConTRolled)-Register ist das erste großflächige, multizentrische Register für TLE-Patienten in Europa. Es wird von der European Heart Rhythm Association (EHRA) realisiert und von der ESC EURObservational Research Department verwaltet. Primärziel des Registers ist es, die kurz- und langfristige Sicherheit von TLE zu erfassen; sekundär dazu sollen die Patienteneigenschaften, die Elektroden, die Indikationen für TLE, und die Instrumente und Techniken, die aktuell für das Verfahren verwendet werden, beschrieben und festgehalten werden. Rund 100 Herzzentren in europäischen Ländern werden freiwillig teilnehmen; diese werden anonym eingetragen und stratifiziert nach Aktivitätsvolumen in Hochvolumen- (> 30 Patienten/Jahr) und Niedrigvolumenzentren (≤ 30 Patienten/Jahr). Jedes teilnehmende Zentrum muss alle konsekutiv bewertete TLE-Patienten, die zwischen November 2012 und Januar 2014 einer TLE unterzogen wurden bzw. werden, eintragen und 1 Jahr lang nach der OP beobachten. Ziel dabei ist es, einen ausreichend großen Probenumfang für die statistische Analyse zu erreichen (mindestens 3.500 Patienten). Sämtliche Daten werden mit einem webbasierten System gesammelt und in zufällig ausgewählten Zentren überprüft. Offizieller Startschuss war am 6. November 2012. Seitdem haben sich 89 Zentren gemeldet, davon sind 65 – diejenigen, die bereits die Zustimmung des eigenen Ethikkomitees haben – jetzt aktiv. Das Ergebnis: bis Ende Juni 2013 waren bereits 1.099 Patienten eingetragen. Die Unabhängigkeit des Registers, die konsekutive Patienteneintragung und die Überwachung der Studie werden gemeinsam zur wissenschaftlichen Validität der erreichten Zielen beitragen.
- Open Access
- 1 June 2005
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 7 (s1) , 156-157
Automatic threshold evolution — New algorithms
- 1 June 2005
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 7 (s1) , 156-157
Open AccessAutomatic threshold evolution — New algorithms
- Open Access
- 1 December 2003
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 4 (Supplement) , B44
A29-1 Laser assisted lead extraction; a seven year single center experience
- 1 December 2003
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 4 (Supplement) , B44
Open AccessA29-1 Laser assisted lead extraction; a seven year single center experience